Home Cart 0 Sign in  
X

[ CAS No. 40473-07-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 40473-07-2
Chemical Structure| 40473-07-2
Chemical Structure| 40473-07-2
Structure of 40473-07-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 40473-07-2 ]

Related Doc. of [ 40473-07-2 ]

Alternatived Products of [ 40473-07-2 ]

Product Details of [ 40473-07-2 ]

CAS No. :40473-07-2 MDL No. :MFCD00088345
Formula : C6H6BrNO Boiling Point : -
Linear Structure Formula :- InChI Key :KMODISUYWZPVGV-UHFFFAOYSA-N
M.W : 188.02 Pubchem ID :256810
Synonyms :

Calculated chemistry of [ 40473-07-2 ]

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.17
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 38.43
TPSA : 22.12 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.3 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.22
Log Po/w (XLOGP3) : 3.02
Log Po/w (WLOGP) : 1.85
Log Po/w (MLOGP) : 1.33
Log Po/w (SILICOS-IT) : 2.04
Consensus Log Po/w : 2.09

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.34
Solubility : 0.0868 mg/ml ; 0.000462 mol/l
Class : Soluble
Log S (Ali) : -3.15
Solubility : 0.133 mg/ml ; 0.000709 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.01
Solubility : 0.185 mg/ml ; 0.000986 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.88

Safety of [ 40473-07-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 40473-07-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 40473-07-2 ]
  • Downstream synthetic route of [ 40473-07-2 ]

[ 40473-07-2 ] Synthesis Path-Upstream   1~26

  • 1
  • [ 40473-07-2 ]
  • [ 6628-77-9 ]
Reference: [1] Australian Journal of Chemistry, 1982, vol. 35, # 10, p. 2025 - 2034
  • 2
  • [ 40473-07-2 ]
  • [ 17920-35-3 ]
Reference: [1] Chemical Communications, 2010, vol. 46, # 6, p. 925 - 927
[2] Patent: WO2009/5672, 2009, A1, . Location in patent: Page/Page column 66
  • 3
  • [ 40473-07-2 ]
  • [ 107-21-1 ]
  • [ 17920-35-3 ]
Reference: [1] Tetrahedron Letters, 2001, vol. 42, # 19, p. 3251 - 3254
  • 4
  • [ 40473-07-2 ]
  • [ 544-92-3 ]
  • [ 83621-01-6 ]
YieldReaction ConditionsOperation in experiment
44% at 20 - 165℃; for 15 h; [Referential Example 21]; 6-Methoxypyridine-2-carbonitrile; Copper(I) cyanide (2.68 g) was added to 2-bromo-6-methoxypyridine (5.62 g) in N,N-dimethylformamide (112 mL) at room temperature, followed by stirring at 165°C for 15 hours. The resultant mixture was cooled in air. Water and ethyl acetate was added to the mixture. The insoluble matter that was formed in the mixture was filtered by Celite. The filtrate was partitioned between water and ethyl acetate. The organic layer was dried over sodium sulfate anhydrate, followed by filtration. The solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane - ethyl acetate), to thereby give the title compound as a solid substance (1.78 g, 44percent) .1H-NMR(400MHz,CDCl3)δ: 3.96(3H,s), 6.95-6.98(1H,m), 7.29-7.31(1H,m), 7.64-7.67(1H,m). MS (EI)m/z: 134 (M+) .
Reference: [1] Synlett, 2001, # 6, p. 765 - 768
[2] Journal of the Chemical Society. Perkin Transactions 1, 2002, vol. 2, # 1, p. 58 - 68
[3] Patent: EP1591443, 2005, A1, . Location in patent: Page/Page column 33
  • 5
  • [ 557-21-1 ]
  • [ 40473-07-2 ]
  • [ 83621-01-6 ]
Reference: [1] Organic Letters, 2015, vol. 17, # 2, p. 202 - 205
[2] Tetrahedron Letters, 2004, vol. 45, # 48, p. 8895 - 8897
  • 6
  • [ 40473-07-2 ]
  • [ 83621-01-6 ]
YieldReaction ConditionsOperation in experiment
39% at 20 - 100℃; for 16 h; Synthesis of 6-methoxypicolinonitrile:To a stirred solution of 2-bromo-6-methoxypyridine (5.0 g, 26.59 mmol) in DMF (50 mL) was added Cu(I)cyanide (7.14 g, 79.77 mmol) at room temperature. The resulting reaction mixture was heated at 100 °C and stirred for 16 h. The reaction mixture was diluted with water, filtered through a pad of celite and the filtrate was extracted with EtOAc. Combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude product. The crude material was purified by silica gel column chromatography to afford 6-methoxypicolinonitrile (1.4 g, 39percent) as white solid. 1H-NMR (DMSO d6, 400 MHz): δ 7.94 (t, 1H), 7.64 (d, 1H), 7.18 (d, 1H), 3.92 (s, 3H); LC-MS: 99.14percent; 135.8 (M++l); (column; X-bridge C-18, (50x3.0 mm, 3.5μ); RT 3.31 min. 0.1percent Aq TFA: ACN; 0.8 ml/min); TLC: 10percent EtOAc/Hexane (Rf:
39% at 100℃; for 16 h; Synthesis of 6-methoxypicolinonitrile [0524] To a stirred solution of 2-bromo-6-methoxypyridine (5.0 g, 26.59 mmol) in DMF (50 mL) was added Cu(I)cyanide (7.14 g, 79.77 mmol) at room temperature. The resulting reaction mixture was heated at 100 °C and stirred for 16 h. The reaction mixture was diluted with water, filtered through a pad of celite and the filtrate was extracted with EtOAc. Combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude product. The crude material was purified by silica gel column chromatography to afford 6-methoxypicolinonitrile (1.4 g, 39percent) as white solid. 1H-NMR (DMSO d6, 400 MHz): δ 7.94 (t, IH), 7.64 (d, IH), 7.18 (d, IH), 3.92 (s, 3H); LC-MS: 99.14percent; 135.8 (M++l); (column; X-bridge C-18, (50x3.0 mm, 3.5μ); RT 3.31 min. 0.1percent Aq TFA: ACN; 0.8 ml/min); TLC: 10percent EtOAc/Hexane (Rf: 0.3).
Reference: [1] Patent: WO2012/40230, 2012, A1, . Location in patent: Page/Page column 86
[2] Patent: WO2013/142269, 2013, A1, . Location in patent: Paragraph 0523; 0524
  • 7
  • [ 40473-07-2 ]
  • [ 26256-72-4 ]
Reference: [1] Patent: WO2012/40230, 2012, A1,
[2] Patent: WO2013/142269, 2013, A1,
  • 8
  • [ 40473-07-2 ]
  • [ 17228-64-7 ]
Reference: [1] Chemical Communications, 2012, vol. 48, # 76, p. 9468 - 9470
  • 9
  • [ 40473-07-2 ]
  • [ 68-12-2 ]
  • [ 54221-96-4 ]
Reference: [1] European Journal of Organic Chemistry, 2002, # 13, p. 2126 - 2135
[2] Synthesis, 2012, vol. 44, # 5, p. 735 - 746
[3] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 8, p. 3130 - 3141
[4] Tetrahedron, 2005, vol. 61, # 26, p. 6207 - 6217
[5] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 24, p. 6763 - 6770
[6] Journal of Organic Chemistry, 1990, vol. 55, # 1, p. 69 - 73
[7] Patent: US2008/103130, 2008, A1, . Location in patent: Page/Page column 50
[8] Patent: US2007/173508, 2007, A1, . Location in patent: Page/Page column 90
  • 10
  • [ 626-05-1 ]
  • [ 124-41-4 ]
  • [ 40473-07-2 ]
YieldReaction ConditionsOperation in experiment
89% at 120℃; for 19 h; [Referential Example 20] ;2-Bromo-6-methoxypyridine; In an argon atmosphere, sodium methoxide (1.82 g) was added to 2,6-dibromopyridine (8.0 g) in toluene (120 mL), followed by stirring at 120°C for 13 hours. Subsequently, sodium methoxide (0.728 g) was added to the mixture, followed by stirring at 120°C for 6 hours. The mixture was cooled in air. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was dried over sodium sulfate anhydrate, followed by filtration. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane - ethyl acetate), to thereby give the title compound in an oily substance (5.64 g, 89percent).1H-NMR(400MHz,CDCl3)δ: 3.93(3H,s), 6.68(1H,d,J=8.0Hz), 7.05(1H,d,J=7.2Hz), 7.39-7.42(1H,m).
Reference: [1] Bulletin des Societes Chimiques Belges, 1986, vol. 95, # 11, p. 1009 - 1020
[2] Patent: EP1591443, 2005, A1, . Location in patent: Page/Page column 33
[3] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 8, p. 3130 - 3141
[4] Journal of the American Chemical Society, 2002, vol. 124, # 35, p. 10443 - 10450
[5] Tetrahedron, 2010, vol. 66, # 4, p. 862 - 870
[6] Journal of Organic Chemistry, 1990, vol. 55, # 1, p. 69 - 73
[7] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 24, p. 6763 - 6770
[8] Patent: EP1375496, 2004, A1, . Location in patent: Page 36; 28
[9] Patent: US2008/207902, 2008, A1, . Location in patent: Page/Page column 63-64
  • 11
  • [ 626-05-1 ]
  • [ 67-56-1 ]
  • [ 40473-07-2 ]
YieldReaction ConditionsOperation in experiment
7 g at 15 - 25℃; for 3 h; Step A 2-bromo-6-methoxypyridine (3a)
To a solution of sodium metal (1.5 g, 62 mmol) in methanol (200 mL) stirred at room temperature for 10 min was added 2,6-dibromopyridine (10 g, 46 mmol). The resulting solution was stirred at room temperature for 3 h. The reaction mixture was quenched with dilute HCl and then extracted with dichloromethane. The combined organic layer was washed with water, brine successively, dried over anhydrous Na2SO4; filtered and concentrated under reduced pressure. The resulting crude product was purified by column by eluting with 5percent ethyl acetate in petroleum ether (v/v) to afford 2-bromo-6-methoxypyridine (7 g). MM-ESI+APCI [M+H]+m/z 187.8.
Reference: [1] Journal of Organic Chemistry, 2004, vol. 69, # 23, p. 7816 - 7821
[2] Synlett, 2001, # 6, p. 765 - 768
[3] Journal of the Chemical Society. Perkin Transactions 1, 2002, vol. 2, # 1, p. 58 - 68
[4] Tetrahedron, 2005, vol. 61, # 26, p. 6207 - 6217
[5] Journal of the American Chemical Society, 1994, vol. 116, # 8, p. 3657 - 3658
[6] Patent: WO2015/50798, 2015, A1, . Location in patent: Page/Page column 50
  • 12
  • [ 626-05-1 ]
  • [ 40473-07-2 ]
Reference: [1] Tetrahedron, 1985, vol. 41, # 7, p. 1373 - 1384
  • 13
  • [ 27992-32-1 ]
  • [ 74-88-4 ]
  • [ 40473-07-2 ]
Reference: [1] Heterocycles, 1990, vol. 31, # 5, p. 819 - 824
  • 14
  • [ 626-05-1 ]
  • [ 40473-07-2 ]
Reference: [1] Patent: US6599917, 2003, B1,
  • 15
  • [ 40473-07-2 ]
  • [ 68-12-2 ]
  • [ 63071-12-5 ]
Reference: [1] Patent: WO2011/28395, 2011, A1, . Location in patent: Page/Page column 20-21
  • 16
  • [ 40473-07-2 ]
  • [ 63071-12-5 ]
Reference: [1] Patent: WO2012/40230, 2012, A1,
[2] Patent: WO2013/142269, 2013, A1,
  • 17
  • [ 40473-07-2 ]
  • [ 127-19-5 ]
  • [ 21190-93-2 ]
Reference: [1] ChemPlusChem, 2016, vol. 81, # 10, p. 1123 - 1128
  • 18
  • [ 40473-07-2 ]
  • [ 5140-72-7 ]
Reference: [1] Synthetic Communications, 1990, vol. 20, # 19, p. 2971 - 2977
[2] Journal of Chemical Research - Part S, 1996, # 4, p. 194 - 195
  • 19
  • [ 40473-07-2 ]
  • [ 103505-54-0 ]
Reference: [1] Liebigs Annalen der Chemie, 1992, # 9, p. 953 - 960
[2] Liebigs Annalen der Chemie, 1992, # 9, p. 953 - 960
[3] Journal of the American Chemical Society, 2016, vol. 138, # 16, p. 5433 - 5440
  • 20
  • [ 40473-07-2 ]
  • [ 182275-70-3 ]
Reference: [1] Synthesis, 2012, vol. 44, # 5, p. 735 - 746
[2] Chemistry - A European Journal, 2010, vol. 16, # 41, p. 12425 - 12433
[3] Tetrahedron, 1996, vol. 52, # 35, p. 11385 - 11404
[4] Chemistry - A European Journal, 1998, vol. 4, # 1, p. 67 - 83
[5] Journal of Organic Chemistry, 2018, vol. 83, # 5, p. 2840 - 2846
  • 21
  • [ 40473-07-2 ]
  • [ 623942-84-7 ]
Reference: [1] Patent: WO2011/28395, 2011, A1,
  • 22
  • [ 40473-07-2 ]
  • [ 73183-34-3 ]
  • [ 1034297-69-2 ]
Reference: [1] Patent: WO2008/74997, 2008, A1, . Location in patent: Page/Page column 88
[2] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 12, p. 2496 - 2500
  • 23
  • [ 40473-07-2 ]
  • [ 909720-21-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 11, p. 3307 - 3312
[2] Patent: US2008/207902, 2008, A1, . Location in patent: Page/Page column 64
  • 24
  • [ 40473-07-2 ]
  • [ 124-38-9 ]
  • [ 1060806-62-3 ]
YieldReaction ConditionsOperation in experiment
42.9%
Stage #1: With 2,2,6,6-tetramethyl-piperidine; n-butyllithium In tetrahydrofuran; hexanes at -78℃; Inert atmosphere
Stage #2: at -78 - 20℃; for 3 h;
Stage #3: With water In tetrahydrofuran; hexanes; ethyl acetateAcidic aqueous solution
Preparation 21 : 2-methoxy-6-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)- nicotinamide; Step 1 : ψ-bromo^-methoxy-nicotinic acid; A solution of 2,2,6,6-tetramethylpiperidine (0.766 g, 5.32 mmol) in tetrahydrofuran (5 mL) was cooled to -78°C under nitrogen. 2.5M n-butyllithium in hexanes (2.34 ml_, 0.375 g, 5.85 mmol) and the mixture was stirred at -780C for 30 min. To the reaction mixture was added a solution of 2-bromo-6-methoxypridine (1.00 g, 5.32mmol) in tetrahydrofuran (5 mL) dropwise. The reaction was stirred at -78°C for 1 h. After this time, an excess of dry ice was added to the reaction mixture and the reaction was allowed to warm to room temperature for 3 h. To the mixture was added water and ethyl acetate, the layers were separated. The aqueous layer was acidified to pH 4. The aqueous layer was extracted 3 times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated to an off-white solid (0.530 g, 42.9 percent) 1 H NMR (500 MHz, DMSO-d6) δ ppm 2.52 (2 H, br. s.), 3.32 (1 H, br. s.), 3.92 (1 H, m), 3.90 (1 H, d, J=2.9 Hz), 8.03 (1 H, d, J=7.8 Hz).
Reference: [1] Patent: WO2010/116282, 2010, A1, . Location in patent: Page/Page column 60
  • 25
  • [ 40473-07-2 ]
  • [ 141-78-6 ]
  • [ 1060806-62-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 10, p. 4273 - 4288
  • 26
  • [ 40473-07-2 ]
  • [ 1009735-24-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 10, p. 4273 - 4288
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 40473-07-2 ]

Bromides

Chemical Structure| 89466-18-2

[ 89466-18-2 ]

6-Bromo-2-methoxypyridin-3-amine

Similarity: 0.88

Chemical Structure| 1802489-60-6

[ 1802489-60-6 ]

(6-Bromo-2-methoxypyridin-3-yl)methanol

Similarity: 0.86

Chemical Structure| 1802489-58-2

[ 1802489-58-2 ]

(6-Bromo-2-methoxypyridin-3-yl)methanamine

Similarity: 0.82

Chemical Structure| 1805208-46-1

[ 1805208-46-1 ]

6-Bromo-3-(bromomethyl)-2-methoxypyridine

Similarity: 0.81

Chemical Structure| 1060810-41-4

[ 1060810-41-4 ]

2-Bromo-6-methoxynicotinaldehyde

Similarity: 0.80

Ethers

Chemical Structure| 89466-18-2

[ 89466-18-2 ]

6-Bromo-2-methoxypyridin-3-amine

Similarity: 0.88

Chemical Structure| 1802489-60-6

[ 1802489-60-6 ]

(6-Bromo-2-methoxypyridin-3-yl)methanol

Similarity: 0.86

Chemical Structure| 1802489-58-2

[ 1802489-58-2 ]

(6-Bromo-2-methoxypyridin-3-yl)methanamine

Similarity: 0.82

Chemical Structure| 1805208-46-1

[ 1805208-46-1 ]

6-Bromo-3-(bromomethyl)-2-methoxypyridine

Similarity: 0.81

Chemical Structure| 1060810-41-4

[ 1060810-41-4 ]

2-Bromo-6-methoxynicotinaldehyde

Similarity: 0.80

Related Parent Nucleus of
[ 40473-07-2 ]

Pyridines

Chemical Structure| 89466-18-2

[ 89466-18-2 ]

6-Bromo-2-methoxypyridin-3-amine

Similarity: 0.88

Chemical Structure| 1802489-60-6

[ 1802489-60-6 ]

(6-Bromo-2-methoxypyridin-3-yl)methanol

Similarity: 0.86

Chemical Structure| 1802489-58-2

[ 1802489-58-2 ]

(6-Bromo-2-methoxypyridin-3-yl)methanamine

Similarity: 0.82

Chemical Structure| 1805208-46-1

[ 1805208-46-1 ]

6-Bromo-3-(bromomethyl)-2-methoxypyridine

Similarity: 0.81

Chemical Structure| 1060810-41-4

[ 1060810-41-4 ]

2-Bromo-6-methoxynicotinaldehyde

Similarity: 0.80